BioCentury | Aug 9, 2019
Company News

Aug. 8 Company Quick Takes: Amarin tumbles on Vascepa update; plus Alexandria, Cambrex, Kala and miRagen

...extend its cash runway into 2Q20. Targets: miR-29 - MicroRNA-29; miR-92a - MicroRNA-92a; miR-155 - MicroRNA-155; BioCentury...
BioCentury | Apr 19, 2019
Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

...inhibitory factor (MIF) Mammalian target of rapamycin (mTOR) (FRAP) (RAFT1) MAP kinase 12 (MAPK12) (ERK-3) (p38 gamma) MicroRNA-155 (miR-155) NLR...
BioCentury | Jun 22, 2018
Preclinical News

Alzheimer's disease linked to herpesvirus

...testing identified genes regulated by HHV-6A, including microRNA-155 (miR-155), which affects the brain's neuronal fraction. miR-155...
...been shown to regulate T cell response to AD. In a mouse model of amyloidosis, miR-155...
...miR-155, a potential mediator of neuronal loss. Elizabeth S. Eaton Icahn School of Medicine at Mount Sinai MicroRNA-155 (miR-155...
BioCentury | Oct 21, 2017
Product Development

Naked ambition

...or 900 mg doses of subcutaneous or IV MRG-106, a synthetic oligonucleotide that inhibits microRNA-155 (miR-155...
...achieves broad distribution, microRNAs with important functions in non-diseased tissue will not be suitable targets. miR-155...
...the U.S. and Japan. miRagen’s fourth program is MRG-107 . Like MRG-106, it also targets miR-155...
BioCentury | Oct 20, 2017
Clinical News

miRagen reports Phase I data of systemic microRNA therapy in CTCL

...for a systemic anti-microRNA therapy in oncology. MRG-106 is a synthetic microRNA antagonist of microRNA-155 (miR-155...
...Boulder, Colo. Product: MRG-106 Business: Cancer Molecular target: MicroRNA-155 (miR-155) Description: Synthetic microRNA antagonist of miR-155...
...Status: Interim Phase I data Milestone: Additional Phase I data (12/2017) Elizabeth S. Eaton MRG-106 Miragen Therapeutics Inc. MicroRNA-155 (miR-155) European...
BioCentury | Oct 13, 2017
Clinical News

miRagen reports systemic microRNA therapy data in CTCL

...600 or 900 mg doses of subcutaneous or IV MRG-106, a synthetic microRNA antagonist of microRNA-155...
...the therapy next year. miRagen gained $0.21 to $9.42 on Friday. Elizabeth S. Eaton MRG-106 Miragen Therapeutics Inc. MicroRNA-155 (miR-155...
BioCentury | Nov 3, 2016
Company News

Signal, miRagen deal

...27% and Signal's shareholders will own 4%. miRagen’s MRG-106 , a synthetic miRNA antagonist of miR-155...
...Inc. (NASDAQ:SGNL), New York, N.Y. Business: Cancer, Cardiovascular, Neurology Jaime De Leon MRG-106 MRG-201 miRagen Therapeutics Inc. Signal Genetics Inc. MicroRNA-155 (miR-155) MicroRNA-29b...
BioCentury | Nov 1, 2016
Company News

miRagen finds public path via Signal merger

...will own 27% and Signal's shareholders 4%. miRagen’s MRG-106 , a synthetic miRNA antagonist of miR-155...
...to $0.50 on Tuesday. Jaime De Leon MRG-106 MRG-201 Myeloma Prognostic Risk Signature (MyPRS) test miRagen Therapeutics Inc. Signal Genetics Inc. MicroRNA-155 (miR-155) MicroRNA-29...
BioCentury | Sep 22, 2016
Distillery Therapeutics

Therapeutics: Protein kinase B (AKT; AKT1; PKB; PKBA); microRNA-155 (miR-155)

...Infectious disease INDICATION: Leishmaniasis Cell culture and mouse studies suggest inhibiting the miR-155 /AKT signaling pathway...
...within disease lesions compared with normal miR-155 expression. Next steps could include identifying and testing miR-155...
...lateral sclerosis (ALS). TARGET/MARKER/PATHWAY: Protein kinase B (AKT; AKT1 ; PKB ; PKBA ); microRNA-155 (miR-155...
BioCentury | Mar 7, 2016
Clinical News

MRG-106: Phase I started

...Boulder, Colo. Product: MRG-106 Business: Cancer Molecular target: MicroRNA-155 (miR-155) Description: Synthetic microRNA antagonist of miR-155...
Items per page:
1 - 10 of 32